Table 5. Independent risk factors for PAN recurrence.
| Variables | aHR (95% CI) | p-value | |
|---|---|---|---|
| Histology | |||
| SCC | 1.00 | - | |
| Non-SCC | 1.08 (0.74–1.58) | 0.680 | |
| Tumor size (cm) | |||
| ≤4.0 | 1.00 | - | |
| >4.0 | 1.22 (0.85–1.76) | 0.290 | |
| Parametrial involvement | |||
| No | 1.00 | - | |
| Yes | 1.67 (1.14–2.45) | 0.009 | |
| Deep stromal invasion | |||
| No | 1.00 | - | |
| Yes | 0.83 (0.53–1.31) | 0.430 | |
| LVSI | |||
| Absence | 1.00 | - | |
| Presence | 1.95 (1.15–3.31) | 0.014 | |
| Corpus invasion | |||
| No | 1.00 | - | |
| Yes | 1.36 (0.91–2.02) | 0.140 | |
| Peritoneal cytology | |||
| No malignancy | 1.00 | - | |
| Malignancy | 1.49 (0.98–2.25) | 0.060 | |
| Not performed | 0.47 (0.13–1.71) | 0.260 | |
| Ovarian metastasis | |||
| No | 1.00 | - | |
| Yes | 2.60 (1.03–6.58) | 0.044 | |
| PLN | |||
| No metastasis | 1.00 | - | |
| Single metastasis | 2.49 (1.36–4.54) | 0.003 | |
| Multiple metastasis | 8.11 (5.16–12.7) | <0.001 | |
| Neoadjuvant chemotherapy | |||
| No | 1.00 | - | |
| Yes | 2.25 (1.56–3.24) | <0.001 | |
| Adjuvant treatment | |||
| None* | 1.00 | - | |
| RT-based | 1.26 (0.66–2.41) | 0.480 | |
| Chemotherapy | 0.91 (0.45–1.86) | 0.800 | |
A Cox proportional hazard regression model for multivariate analysis. All the listed covariates were entered in the final model. Significant p-values were emboldened.
aHR, adjusted hazard ratio, CI, confidence interval; LVSI, lympho-vascular space invasion; PAN, para-aortic lymph node; PLN, pelvic lymph node; RT, whole pelvic radiotherapy; SCC, squamous cell carcinoma.